Search Results
Feb 18, 2026, 07:00 ET Finding Hope for Frizzle (FRRS1L) and Apertura Gene Therapy Announce License Agreement for the Development of a Gene Therapy Using TfR1 CapX, an AAV Capsid Designed to Target the Central Nervous System
information about this relationship and the gene therapy.FRRS1L disease, also known as early infantile epileptic encephalopathy type 37, is a rare, recessive genetic disease resulting from loss of function mutations in the FRRS1L gene. The FRRS1L gene encodes a protein that is required for
More news about: Apertura Gene Therapy
Feb 17, 2026, 12:17 ET Young Immigrants Advancing Biomedical Science Eligible for $50,000 Vilcek Prizes for Creative Promise
array of groundbreaking research. Past prizewinners include Feng Zhang, for his role in the development of the gene editing software, CRISPR; Markita del Carpio Landry for her breakthroughs in gene-editing technologies that can be utilized in agriculture and the development of biologic drugs; and Gerta Hoxhaj
More news about: The Vilcek Foundation
Feb 17, 2026, 11:42 ET Growth Factors Market to Reach US$ 3.7 Bn by 2033, Expands Amid Rising Regenerative Medicine and Biopharmaceutical Innovation - Persistence Market Research
Market expansion stems from increasing demand for regenerative therapies, advances in biopharmaceutical manufacturing, and growing investment in cell and gene therapies. Growth factors enable therapeutic innovation, tissue engineering protocols, and high-precision biologics production, making them indispensable
More news about: Persistence Market Research Pvt. Ltd.
Feb 17, 2026, 10:55 ET Database Management System (DBMS) Market Driven by Cloud Adoption, Big Data Analytics, and Rising Enterprise Digital Transformation at a CAGR of 5.5% : - Market Research Intellect
II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare Disease Therapeutics, Cell and Gene Therapy Platforms, Respiratory and Immunology Applications, Neuromuscular
More news about: Market Research Intellect
Feb 17, 2026, 10:40 ET Financial Wellness Benefits Market Poised for Robust Expansion Amid Rising Employer Focus on Workforce Well-Being and Digital Financial Planning Solutions - Market Research Intellect
II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare Disease Therapeutics, Cell and Gene Therapy Platforms, Respiratory and Immunology Applications, Neuromuscular
More news about: Market Research Intellect
Feb 17, 2026, 10:01 ET Companion Animal Diagnostic Market worth $5.40 billion by 2031 | MarketsandMarkets™
technologies, specialized expertise, and GMP-compliant facilities that it lacks in-house. Their focus on innovative platforms, such as novel biologics, gene-based therapies, advanced formulations, and digital health tools, drives high demand for CDMO and CRO support across early-stage R&D, scale-up,
More news about: MarketsandMarkets
Feb 17, 2026, 09:00 ET Renowned Developmental Biologist Wins March of Dimes Prize
diseases, including in pregnancy; discovered ferroportin, the iron transporter gene that delivers the crucial micronutrient from mother to baby; and identified a growth factor that exponentially grows stem cell populations for use in gene therapies for children with blood disorders, including sickle cell anemia.The
More news about: March of Dimes
Feb 17, 2026, 08:04 ET BioLife Solutions to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 26, 2026
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2025 fourth quarter and full year financial results will be released on February 26, 2026. The Company will
More news about: BioLife Solutions, Inc.
Feb 17, 2026, 08:00 ET Andelyn Biosciences to Apply the AAV Curator® Platform to Manufacture Clinical Grade AAV for Drake Rayden Foundation for the Treatment of Nonketotic Hyperglycinemia
for organizations advancing life-changing gene therapies.About Andelyn Biosciences, Inc.Andelyn Biosciences is a full-service cell and gene therapy CDMO focused on the development, characterization, and production of viral vectors for gene therapy. With more than 20 years of experience,
More news about: Andelyn Biosciences
Feb 17, 2026, 08:00 ET Resurrect Bio announces $8.1M initial close of Series A led by Corteva
disease resistance genes that have been suppressed by pathogens. The resurrection process involves making small changes to the native plant genes using gene editing, restoring the crop's ability to defend itself against pathogens. This approach is poised to offer farmers a novel pathway to protect yields
More news about: Resurrect Bio
Feb 17, 2026, 08:00 ET GelMEDIX Completes $13 Million Seed Financing and Announces First Partnership
validation of GelMEDIX's proprietary injectable hydrogel scaffold platform, which is engineered to optimize the delivery, efficacy, and safety of cell and gene therapies. Michael J. Cima, PhD, David H. Koch Professor of Engineering at the Massachusetts Institute of Technology, and Parinaz Motamedy, MBA, Partner,
More news about: GelMEDIX
Feb 17, 2026, 08:00 ET Waters Introduces Next-Generation Microflow LC Columns with MaxPeak Premier Technology, Delivering Higher Sensitivity with Lower Sample and Solvent Usage
DMPK, and 'omics applications.1 Uses up to 75% less sample than 2.1 mm I.D. columns, conserving precious materials such as cell and gene therapy and personalized medicine candidates while delivering deeper insights. 2 Reduces solvent consumption by up to 4× versus
More news about: Waters Corporation
Feb 17, 2026, 08:00 ET Waters Introduces Next-Generation Microflow LC Columns with MaxPeak Premier Technology, Delivering Higher Sensitivity with Lower Sample and Solvent Usage
DMPK, and 'omics applications.1 Uses up to 75% less sample than 2.1 mm I.D. columns, conserving precious materials such as cell and gene therapy and personalized medicine candidates while delivering deeper insights. 2 Reduces solvent consumption by up to 4× versus
More news about: Waters Corporation
Feb 17, 2026, 07:45 ET TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers
relapse rates in AML due to its ability to allow leukemic blasts to evade immune recognition and attack by the patient's immune system. When VSIR, the gene that encodes for VISTA, is removed in murine models of mutNPM1 AML, an immune response is observed and survival is enhanced.TBS-2025 was
More news about: TuHURA Biosciences, Inc.
Feb 17, 2026, 07:42 ET Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting
next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential
More news about: Actinium Pharmaceuticals, Inc.
Feb 17, 2026, 05:33 ET US$350 Trillion Wealth Shift by 2050, But Current AI Boom Risks US$13 trillion Correction
Six systemic technologies are driving a global transformation - artificial intelligence, quantum computing, fusion energy, nanotechnology, gene editing and extended reality. Together they redefine computation, energy, materials, longevity and even the perception of reality itself.The
More news about: The Institute of Strategic Intelligence and Intervention (ISII)
Feb 16, 2026, 19:11 ET RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: THE ROSEN LAW FIRM, P. A.
Feb 16, 2026, 10:46 ET Genotyping Market to Reach $61.6 Billion by 2033 Globally, at 13.8% CAGR: Allied Market Research
are using genetic information to tailor treatments based on the genetic profile of an individual. Genotyping enables clinicians to identify specific gene variations that influence disease risk or drug response. This improves treatment effectiveness and reduces adverse drug reactions.Surge in prevalence
More news about: Allied Market Research
Feb 16, 2026, 10:15 ET CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™
(India), CRISPR Therapeutics (Switzerland), Autolus Therapeutics (UK), Allogene Therapeutics (US), Cartesian Therapeutics, Inc. (US), Guangzhou Bio-gene Technology Co., Ltd (China), and Wugen (US).Market players have adopted various strategies, including new product launches, acquisitions, agreements,
More news about: MarketsandMarkets
Feb 16, 2026, 07:05 ET Zemcelpro® (dorocubicel) receives NUB Status 1 in Germany
haematopoietic stem cells (HSCs) from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop best-in-class cell and gene therapies by leveraging the technologies that form the EnhanceTM platform, including
More news about: ExCellThera
Feb 16, 2026, 07:05 ET Zemcelpro® (dorocubicel) receives NUB Status 1 in Germany
haematopoietic stem cells (HSCs) from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop best-in-class cell and gene therapies by leveraging the technologies that form the EnhanceTM platform, including
More news about: ExCellThera
Feb 16, 2026, 06:45 ET Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
of:Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved testIMPORTANT SAFETY INFORMATION FOR RETEVMO (selpercatinib)Hepatotoxicity: Serious
More news about: Eli Lilly and Company
Feb 16, 2026, 06:30 ET Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories
only, and are powered by R&D Systems antibodies and proteins. With more than 390 analytes across neuroscience, immunology, oncology, and cell and gene therapy, the Simple Plex portfolio enables researchers to maintain consistency and data quality while working efficiently across a wide range of applications."Ella's
More news about: Bio-Techne Corporation
Feb 13, 2026, 18:01 ET Breakthrough Study Confirms HYD LLC's 30-Year Research on Deuterium Modulation in Cancer Gene Expression
2026 /PRNewswire/ -- A newly published scientific paper titled "Gene Expression Patterns in Lung Adenocarcinoma Cells in Response to Changes in Deuterium Concentration" (Csonka, G.I.; Papp, A.; Somlyai, I.; Somlyai, G. Gene Expression Patterns in Lung Adenocarcinoma Cells in Response to Changes
More news about: HYD LLC
Feb 13, 2026, 17:36 ET QURE Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against uniQure N.V.
acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases.
More news about: Robbins LLP